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The Everolimus-Eluting Stent in Real-World Patients
6-Month Follow-Up of the X-SEARCH (Xience V
Stent Evaluated at Rotterdam Cardiac Hospital) Registry
Yoshinobu Onuma, MD, Neville Kukreja, MA, MRCP, Nicolo Piazza, MD,
Jannet Eindhoven, MSC, Chrysafios Girasis, MD, Lisanne Schenkeveld, MSC,
Ron van Domburg, PHD, Patrick W. Serruys, MD, PHD,
on behalf of the Interventional Cardiologists of the Thoraxcenter (2000 to 2007)
Rotterdam, the Netherlands
Objectives The purpose of this study was to investigate the impact of everolimus-eluting stents (EES) in comparison with
bare-metal stents (BMS), sirolimus-eluting stents (SES), and paclitaxel-eluting stents (PES) on the 6-month clini-
cal outcomes in an all-comer population.
Background EES have been shown to be effective in the context of randomized trials with selected patients. The effect of EES
implantation in more complex, unselected patients cannot be directly extrapolated from these findings.
Methods In total, 649 consecutive unselected patients treated exclusively with EES were enrolled. Six-month clinical end
points were compared with 3 historical cohorts (BMS, n  450; SES, n  508; and PES, n  576). Major ad-
verse cardiac events (MACE) were defined as a composite of all-cause mortality, myocardial infarction, or target
vessel revascularization (TVR).
Results The patients treated with EES were older, presented more frequently with acute myocardial infarction, and had
more complicated lesions than the other groups. The EES group demonstrated a higher incidence of all-cause
mortality than the SES group and a lower incidence of TVR than the BMS group. Multivariate adjustment demon-
strated that BMS was associated with higher TVR and MACE risk than EES (adjusted hazard ratio [HR] for TVR:
2.02 [95% confidence interval (CI): 1.11 to 3.67]; adjusted HR for MACE: 2.15 [95% CI: 1.36 to 3.42]); that SES
had a clinical outcome similar to that of EES, and that PES had a higher risk of MACE than did EES (adjusted
HR: 1.57 [95% CI: 1.02 to 2.44]).
Conclusions This study suggests that the use of EES in an unselected population may be as safe as and more effective than
BMS, may be as safe and effective as SES, may be as safe as PES, and may be more effective than PES.
(J Am Coll Cardiol 2009;54:269–76) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.016fl
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uompared with bare-metal stents (BMS), polymer-based
irolimus-eluting stents (SES) and paclitaxel-eluting stents
PES) have been shown to significantly reduce angiographic
estenosis and recurrent ischemia necessitating repeat revas-
ularization (1). Stent thrombosis and endothelial dysfunc-
ion after both PES and SES implantation, however,
emains a concern with this technology. With the goal of
urther enhancing the safety and efficacy of drug-eluting
tents (DES), an everolimus-eluting stent (EES) (Abbott
ascular, Santa Clara, California) has been designed in
hich the antiproliferative agent is released from a thin (7.8
m), nonadhesive, durable, biocompatible fluoropolymer
oated onto a low-profile (0.0813-mm strut thickness),
rom the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.l
Manuscript received February 26, 2009; revised manuscript received April 6, 2009,
ccepted May 13, 2009.exible cobalt chromium stent. Angiographic and clinical
oninferiority of the EES to the PES was proven in the
PIRIT II and III randomized studies (2,3).
The clinical trials completed so far, however, have in-
luded only elective patients with relatively noncomplex
esions and have excluded high-risk patients such as those
resenting with acute myocardial infarction (MI) or those
ith left main stenosis or calcified lesions (2–4). The effect
f EES implantation in complex, unselected patients treated
n daily practice still remains unknown and cannot be
xtrapolated from these randomized controlled trials. We
herefore sought to evaluate the impact of this second-
eneration DES on the clinical outcomes in consecutive
atients treated in a real-life, all-comer population. The aim of
his study was to report the 6-month outcomes of unrestricted
niversal use of EES in patients with de novo coronary artery
esions and to compare its efficacy against our historical
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Unrestricted Use of the Everolimus-Eluting Stent July 14, 2009:269–76BMS, SES, and PES cohort from
the RESEARCH (Rapamycin-
Eluting Stent Evaluated At Rot-
terdam Cardiology Hospital) and
T-SEARCH (Taxus-Stent Eval-
uated At Rotterdam Cardiology
Hospital) registries.
Methods
Study design and patient popu-
lation. The X-SEARCH (Xience
Stent Evaluated At Rotterdam
Cardiology Hospital) registry is a
prospective single-center registry
with the main purpose of evaluat-
ing the safety and efficacy of EES
implantation in consecutive un-
selected patients treated in daily
practice. Its conceptual design and
methodology are similar to that of
he RESEARCH and T-SEARCH registries (5,6) and fol-
ows the dynamic registry design described by Rothman and
reenland (7). Since EES received Conformité Européenne
ark approval and became commercially available in Europe in
arch 2007, it has been our policy to utilize the EES as the
evice of choice for every percutaneous coronary intervention
erformed in our institution. All consecutive procedures were
ncluded, without any specific anatomical or clinical restriction.
Between March 1, 2007, and October 31, 2007, 649
onsecutive patients presenting with de novo lesions were
reated exclusively with EES and were included in the
resent report (EES group) after exclusion of patients
reated with EES and other stent types in the same
rocedure (n  48), those treated without stent implanta-
ion (n  20), those treated exclusively with BMS or other
ES (n  17), and those treated with EES for in-stent
Figure 1 Flowchart of Patient Selection
The flowchart represents patient inclusion and exclusion in the X-SEARCH
(Xience Stent Evaluated At Rotterdam Cardiology Hospital) registry. *Occurring
in the short transitional period (2 weeks) between paclitaxel-eluting stent/
everolimus-eluting stent. BMS  bare-metal stent(s); DES  drug-eluting
stent(s); PCI  percutaneous coronary intervention.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationuestenosis (n  44) (Fig. 1). At the initiation of the
-SEARCH registry, EES was available in lengths of 8, 12,
5 and 23 mm and diameters from 2.5 to 4.0 mm. This
ES group was compared with a historical cohort from the
ESEARCH and T-SEARCH registries that comprised 1)
he pre-SES arm of the RESEARCH registry (BMS group,
 450); 2) the active arm of the RESEARCH registry
SES group, n  508); and 3) the PES group of the
-SEARCH registry (PES group, n  576) (Fig. 2).
Written informed consent was obtained from every pa-
ient. All procedures were performed according to standard
linical guidelines at the time of enrollment (8). All patients
ere pre-treated with 300 mg clopidogrel. At least 1 month
f clopidogrel treatment (75 mg/day) was recommended for
atients treated with BMS. Clopidogrel was prescribed for
3 months for patients with SES, or 6 months for
atients with PES, and 12 months for patients with EES,
ccording to the data from the pivotal DES randomized
rials (9,10). Life-long aspirin therapy was recommended
or all patients.
efinitions. Hypercholesterolemia was defined as fasting
otal cholesterol 5 mmol/l (193 mg/dl) or the use of
ipid-lowering therapy. Hypertension was defined as blood
ressure 140/90 mm Hg or the use of antihypertensive
edications. Angiographic success was defined as a residual
tenosis 30% by visual analysis in the presence of TIMI
Thrombolysis In Myocardial Infarction) flow grade 3. The
rimary end point was major adverse clinical events
MACE), defined as all-cause death, nonfatal MI, or target
essel revascularization (11). Secondary end points included
ll-cause mortality, MI, target vessel revascularization
TVR), target lesion revascularization (TLR), definite stent
hrombosis, and the composites of all-cause death or non-
atal MI. MI included reinfarction (defined as recurrence of
ymptoms together with ST-segment elevation or new left
undle branch block and an increase in cardiac enzymes
fter stable or decreasing values) or spontaneous MI (diag-
osed by a rise in creatine kinase-MB fraction of 3 times the
Figure 2 Inclusion Periods
of X-SEARCH and Historical Cohorts
Chronological order of 4 cohorts included in analysis: BMS, everolimus-eluting
stent (EES), paclitaxel-eluting stent (PES), and SES. X-SEARCH  Xience Stent
Evaluated At Rotterdam Cardiology Hospital; other abbreviations as in Figure 1.pper limit of normal together with symptoms and either
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July 14, 2009:269–76 Unrestricted Use of the Everolimus-Eluting Stenthe development of ST-segment elevation or new left
undle branch block) (12). TVR was defined as a repeat
evascularization of a lesion in the same epicardial vessel
reated in the index procedure (13). TLR was defined as a
epeat intervention in the stent or within 5 mm proximal or
istal to the stent. Stent thrombosis was defined as angio-
raphically defined thrombosis with TIMI flow grade 0 or 1
r the presence of flow-limiting thrombus, accompanied by
cute symptoms, irrespective of whether there had been an
nterceding reintervention (14). The timing of stent throm-
osis was categorized as early (within 30 days after implan-
ation), late (between 30 days and 1 year) or very late (1
atient CharacteristicsTable 1 Patient Characteristics
BMS
(n  450) (
Age, yrs 61  11
Female 28.6
Current smoker 34.0
Diabetes mellitus 14.9
Noninsulin dependent 10.9
Insulin dependent 4
Hyperlipidemia 55.3
Hypertension 47.6
Family history of coronary artery disease 28.2
Previous MI 39.7
Previous CABG 8.0
Previous PCI 18.0
Clinical presentation
Stable angina 47.6
Unstable angina/NSTEMI 34.7
STEMI 17.8
Cardiogenic shock 2.0
No. of vessels diseased 1.6  0.7 1
Multivessel disease 47.8
No. of lesions treated 1.8  0.9 2
ACC/AHA lesion classification*
Type A 19.6
Type B1 31.8
Type B2 49.6
Type C 29.8
Bifurcation 7.8
Treated vessels†
LMS 2.2
RCA 34.0
LAD 59.3
LCx 33.1
SVG 2.0
Number of stents 1.9  1.2 2
Average stent diameter, mm 3.1  0.3 2
Total stent length, mm 30  20
Clopidogrel duration, months 1.0  0.1 4
Procedural success 97.3
ata are presented as % or mean  SD *Expressed as percentage of patients with each lesion typ
BMS  bare-metal stent(s); CABG  coronary artery bypass graft surgery; EES  everolimus-elu
I  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction; PCI  pe
irolimus-eluting stent(s); STEMI  ST-segment elevation myocardial infarction; SVG  saphenousear) (11). lollow-up data. Survival data for all patients were ob-
ained from municipal civil registries at 1 and 6 months after
he procedure. A questionnaire was subsequently sent to all
iving patients with specific queries on rehospitalization and
ACE. As the principal regional cardiac referral center,
ost repeat revascularizations (either percutaneous or sur-
ical) are usually performed at our institution and recorded
rospectively in our database. For patients who suffered an
dverse event at another center, medical records or discharge
etters from the other institutions were systematically re-
iewed. General practitioners and referring physicians were
ontacted for additional information if necessary. Over the
08)
PES
(n  576)
EES
(n  649) p Value
11 62  11 64  12 0.001
1 26.4 28.4 0.22
7 29.0 30.0 0.36
7 18.4 20.8 0.1
8 13.2 14.4 0.32
9 5.2 6.4 0.37
5 62.2 47.6 0.001
3 41.8 49.3 0.01
5 40.6 45.4 0.001
2 34.5 25.9 0.001
3 6.1 7.3 0.25
18.2 15.3 0.37
6 45.3 38.8 0.03
1 27.0 20.2 0.001
1 28.0 39.3 0.001
8 3.8 6.0 0.001
0.8 1.8  0.8 1.8  0.9 0.006
1 56.1 50.2 0.03
1.0 1.7  0.9 1.8  1.0 0.001
9 7.3 6.5 0.001
7 25.0 31.1 0.049
6 54.3 51.5 0.25
5 47.2 38.9 0.001
7 15.9 22.2 0.001
9 4.3 7.6 0.001
5 37.7 33.9 0.25
5 55.2 38.7 0.001
6 33.2 19.1 0.001
3 3.3 4.0 0.33
1.4 2.2  1.5 2.1  1.4 0.001
0.2 3.0  0.3 3.1  0.3 0.001
24 43  31 57  26 0.001
2.0 6.0  0 11.9  0.7 0.001
2 97.4 98.3 0.4
e total 100%. †Expressed as percentage of patients with each vessel type, hence total 100%.
nt(s); LAD  left anterior descending artery; LCx  left circumflex artery; LMS  left main stem;
ous coronary intervention; PES  paclitaxel-eluting stent(s); RCA  right coronary artery; SES 
raft.SES
n  5
61 
32.
30.
17.
11.
5.
55.
41.
32.
30.
9.
188
44.
37.
18.
1.
.8 
54.
.0 
21.
30.
48.
42.
15.
2.
38.
58.
31.
3.
.1 
.8 
39 
.0 
97.
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Unrestricted Use of the Everolimus-Eluting Stent July 14, 2009:269–76hysicians from the local catchment area has encouraged a
igh level of data collection and source documentation.
tatistical analysis. Continuous variables are presented as
ean  SD, whereas categorical variables are expressed as
ercentages. Categorical variables were compared using
earson chi-square test or Fisher exact test, and continuous
ariables were compared using the F test for analysis of
Figure 3 Unadjusted Survival Curves
Kaplan-Meier survival curves stratified according to the stent types: (A) all-cause d
ization; and (D) the composite of major adverse cardiac events (all-cause mortality
(green lines); PES (yellow lines); SES (red lines). Abbreviations as in Figures 1 a
umulative Incidence of Definite Stent ThrombosisTable 2 Cumulative Incidence of Definite Stent Thrombosis
BMS
(n  450)
SES
(n  50
Early (30 days) 7 (1.6%) 2 (0.4%
Acute (24 h) 4 (0.9%) 1 (0.2%
Subacute (1, 30 days) 3 (0.7%) 1 (0.2%
Late (30 days) 2 (0.4%) 1 (0.2%
Overall (up to 6 months) 9 (2.0%) 3 (0.6%bbreviations as in Table 1.ariance. All statistical tests were 2-tailed, and a p value
0.05 was considered as statistically significant. The crude
urvival curves were constructed with the use of the Kaplan-
eier method to describe the incidence of events over time,
nd log-rank tests were applied to evaluate differences
etween the treatment groups. Patients lost to follow-up
ere considered at risk until the date of last contact, at
(B) the composite of death or myocardial infarction; (C) target vessel revascular-
myocardial infarction, or target vessel revascularization). BMS (black lines); EES
PES
(n  576)
EES
(n  649) p Value
7 (1.2%) 4 (0.6%) 0.19
1 (0.2%) 2 (0.3%) 0.22
6 (1.0%) 2 (0.3%) 0.21
1 (0.2%) 0 (0%) 0.41
8 (1.4%) 4 (0.6%) 0.09eath;
, any
nd 2.8)
)
)
)
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July 14, 2009:269–76 Unrestricted Use of the Everolimus-Eluting Stenthich point they were censored. Adjusted survival curves
ere calculated using Cox regression models. These models
ere built to adjust for multiple potential confounders in the
aseline characteristics for each paired treatment compari-
on. Firstly, a univariate analysis was performed to identify
ignificant variables among the following: age, gender,
ypertension, type 1 or 2 diabetes mellitus, current smoking,
amily history, previous coronary artery bypass graft surgery,
revious MI, previous percutaneous coronary intervention,
linical presentation of acute MI or unstable angina (stable
ngina as a reference), presentation with shock, multivessel
isease, treated vessel, American Heart Association/
merican College of Cardiology lesion type, bifurcation
reatment, number of lesions treated, number of stents
mplanted, average stent diameter, and total stented length.
econd, a Cox model was built forcing stent type and
ignificant variables in the univariate analysis. The stent type
as entered as a categorical variable with EES as the
eference. The results are presented as adjusted hazard ratios
HRs) with 95% confidence intervals (CIs). Statistical
nalysis was performed with SPSS version 16 for Windows
SPSS Inc., Chicago, Illinois).
esults
aseline characteristics are presented in Table 1. Across the
tudy period, patients became progressively older and were
ore likely to have hypertension and present with ST-
egment elevation myocardial infarction (STEMI) or car-
iogenic shock—likely a reflection of changes in disease
resentation with time. Bifurcations, left main disease, and
he use of longer stents were more common in the DES
roups. Fewer EES patients had a history of previous bypass
urgery.
-month clinical outcomes. Clinical follow-up at 6
onths was complete in 99% of patients. The cumulative
ncidences of 6-month clinical end points are presented in
igure 3. The crude all-cause mortality rate was significantly
igher in the EES group than in the SES group: 5.9% in the
ES group versus 3.6%, 3.5%, and 2.8% in the BMS, PES,
nd SES groups, respectively (Fig. 3A). The cumulative
ncidence of all-cause death or any MI was similar in the 4
roups (Fig. 3B). TVR was observed in a significantly lower
ercentage of EES patients than in BMS patients (3.1% vs.
.8%, p  0.04) (Fig. 3C). The composite end point of
ACE was observed in 9.2% of the EES patients; compa-
able event rates were observed in the BMS, SES, and PES
roups (Fig. 3D). The cumulative incidences of definite
tent thrombosis at various time points are shown in Table
. The overall rate of definite stent thrombosis was similar
cross the cohorts (BMS 2.0%, SES 0.6%, PES 1.4%, and
ES 0.6%).
ultivariate analyses. Cox multivariable regression
odels were used to correct for differences across the 4
roups and calculate independent predictors of all-cause
ortality. Cardiogenic shock (adjusted HR: 8.1, 95% CI: 6.3 to 15.5), type 1 diabetes (adjusted HR: 3.3, 95% CI:
.5 to 7.2), presentation with STEMI (adjusted HR: 2.6,
5% CI: 1.4 to 5.0), and multivessel disease (adjusted
R: 2.0, 95% CI: 1.2 to 3.4) were identified as indepen-
ent predictors of 6-month mortality; in contrast, type A
esion classification was protective (adjusted HR: 0.20,
5% CI: 0.1 to 0.8).
Adjusted hazard ratios of pair-wise comparisons of the
ES group to other stent groups are shown in Table 3. The
isks of TVR, MACE, and composite of MI or all-cause
ortality were significantly higher in the BMS than in the
ES group (adjusted HR: 2.02, 2.15, and 1.92, respec-
ively). PES was associated with a higher risk of MACE
han EES was (adjusted HR: 1.57, 95% CI: 1.02 to 2.44).
ES was similar when compared with EES.
The same Cox regression models were used to draw
urvival curves adjusted for differences in baseline char-
cteristics, as presented in Figure 4. After adjustment,
ll-cause mortality was similar among stent types, with a
rend toward better survival in the EES group than in the
MS group (1.5% vs. 3.1%, p  0.059). TVR was
ignificantly lower in the EES group than in the BMS
roup (2.8% vs. 5.8%, p  0.02) but was comparable with
ther DES groups (SES 2.0%, PES 4.6%). The compos-
te end point of MACE was significantly lower in the
ES group than in the BMS group (5.5% vs. 11.0%, p 
.003) and PES group (5.5% vs. 8.6%, p  0.04); the
ES and SES groups had similar MACE rates (5.5% vs.
djusted Hazard Ratios forair-Wise Comparisons Between StentsTable 3 Adjusted Hazard Ratios forPair-Wise Comparisons Between Stents
Adjusted
Hazard Ratio 95% CI
BMS versus EES
All-cause mortality* 1.98 0.97–4.01
MI or all-cause mortality† 1.92 1.14–3.25
TVR‡ 2.02 1.11–3.67
MACE§ 2.15 1.36–3.42
SES versus EES
All-cause mortality* 1.15 0.52–2.55
MI or all-cause mortality† 1.45 0.85–2.47
TVR‡ 0.69 0.33–1.45
MACE§ 1.18 0.71–1.94
PES versus EES
All-cause mortality* 1.01 0.53–1.92
MI or all-cause mortality† 1.49 0.89–2.32
TVR‡ 1.60 0.89–2.88
MACE§ 1.57 1.02–2.44
Themodel for all-causemortality was adjusted for the following variables: age, cardiogenic shock,
ype 1 diabetes, clinical presentation, multivessel disease, type A lesion characteristics. †The
odel for MI or all-cause mortality was adjusted for type 1 diabetes, age, multivessel disease,
linical presentation, cardiogenic shock, number of stent and type A lesion characteristics. ‡The
ox model for TVR is adjusted for diabetes, number of stents, number of treated lesions, and type
2 lesion characteristics. §The model for MACE is adjusted for age, cardiogenic shock, clinical
resentation, multivessel disease, type 1 or 2 diabetes, smoking, and bifurcation.
MACE  major adverse cardiac events (all-cause death, MI, or TVR); TVR  target vessel
evascularization; other abbreviations as in Table 1..1%, p  0.6).
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he X-SEARCH registry, the focus of this report, is a
ontemporary, all-comer, single-center registry of patients
reated with EES. In this registry, patients were older,
resented more frequently with STEMI, and had more
omplicated lesions compared with patients who were
reated in the past with BMS, SES (RESEARCH registry)
nd PES (T-SEARCH registry). At 6-month follow-up,
he EES group demonstrated a higher cumulative incidence
f all-cause mortality than the SES group, and a lower
ncidence of TVR than BMS. Taking into account the
igh-risk patient profile in the X-SEARCH registry, mul-
ivariate adjustment with Cox regression model demon-
trated that 1) EES was associated with lower TVR and
ACE risk than BMS was; 2) EES had a lower MACE
ate than PES did; and 3) EES had clinical outcomes
imilar to SES.
The safety and efficacy of the EES stents have been
emonstrated in low-risk profile patients. The randomized
PIRIT II trial, in which 300 patients were enrolled and
andomly assigned 3:1 to receive an EES (n  223) or a
ES (n 77), was performed in Europe, New Zealand, and
Figure 4 Adjusted Survival Curves
Adjusted survival curves stratified according to the stent types using Cox proportio
tion; (C) target vessel revascularization; and (D) the composite of major adverse c
larization). BMS (black lines); EES (green lines); PES (yellow lines); SES (red linendia. The trial met its primary end point, demonstrating eot only noninferiority, but also superiority with respect to
n-stent late loss at 6 months with EES (0.11  0.27 mm)
ompared with PES (0.36  0.39 mm). No significant
ifferences were present, however, in the secondary end
oints of MACE (cardiac death, MI, or ischemia-driven
LR), presumably because of the small sample size
2,15,16). In the larger SPIRIT III trial performed in the
.S. (3), 1,002 patients with noncomplex coronary artery
isease were randomly assigned 2:1 to treatment with EES
n  669) or PES (n  333). Angiographic follow-up at 8
onths demonstrated a significant reduction in the primary
ngiographic end point of in-segment late loss with EES
ompared with PES. At 1 year, EES was noninferior to
ES for the co-primary clinical end point of target vessel
ailure (cardiac death, MI, or ischemia-driven TVR) and
esulted in a significant reduction in MACE. The lower
ACE risk of EES compared with PES in the current
tudy with all-comer cohorts reconfirms the superiority of
ES over PES, not only in low-risk patients but also in the
igh-risk all-comer populations.
The first-generation DES have been associated with
igher rates of late stent thrombosis and thrombosis-related
zard model: (A) all-cause death; (B) the composite of death or myocardial infarc-
events (all-cause mortality, any myocardial infarction, or target vessel revascu-
breviations as in Figures 1 and 2.nal ha
ardiac
s). Abvents than BMS (17,18). The cause of late stent throm-
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etarding the growth of healthy endothelium over stent
truts and partly due to chemical features of their durable
olymer coating (19–21). The EES, using a novel drug as
ell as a different polymer, might address this issue.
re-clinical studies have shown more rapid endothelializa-
ion and reduced expression of platelet-endothelial cell
dhesion molecule-1 and increased secretion and messenger
ibonucleic acid levels of vascular endothelial growth factor
t 14 days with EES than with SES or PES (22). The
PIRIT III study suggested that thienopyridine discontin-
ation after 6 months might be associated with a lower rate
f subsequent stent thrombosis with EES than with PES
hrough 2 years of follow-up (0.4% vs. 2.6%), although
iven the relatively low rates of stent thrombosis, this
ifference did not reach statistical significance (p 0.10). In
he present study, the rate of overall stent thrombosis at 6
onths was similar in the EES and other stent groups,
lthough there were no incidences of late stent thromboses
ith EES up to 6 months. Larger studies with longer
ollow-up will be necessary to assess the differential effects of
ES on late and very late stent thrombosis.
The low incidence of hypercholesterolemia in the EES
roup might result from the under-diagnosis of hypercho-
esterolemia in the acute MI population, in which the
ncidence of hypercholesterolemia was low (24%). Eighty
ercent of these patients did not have any history related to
therosclerosis, and their cholesterol level was not available
t the time of the procedure.
tudy limitations. This is a single-center, nonrandomized,
bservational study. Because we used consecutive but non-
equential patient data from past registries as historical
ontrols, the baseline patient characteristics vary across the
ohorts. We used Cox regression analysis to address these
ifferences in baseline characteristics; however, the result
an be influenced by the selection of the variables and
uality of data. In the current registry, the data in Table 1,
hich were subsequently used in the Cox regression models,
ere carefully checked by 2 experienced cardiologists, with
eview of medical records and cine-angiograms to ensure
ccurate and complete data entry. In addition, there was no
ias in stent selection, because only 1 stent was available in
ach period of the registries, unlike at other institutions
here the penetration of DES has fluctuated after the ESC
restorm in 2006 (23,24). Our study had inadequate statis-
ical power to detect significant differences in adverse
utcomes associated with low event rates (e.g., late stent
hrombosis). These observations, therefore, can only be used
o generate hypotheses when comparing the EES results
ith those for the other stents.
onclusions
he current analysis of patients treated with EES compared
ith SES, PES, and BMS suggests that the use of EES in
n unselected population, including high-risk patients, maye as safe as and more effective than BMS, may be as safe
nd effective as SES, may be as safe as PES, and may be
ore effective than PES.
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